On Monday, ARS Pharmaceuticals Inc (NASDAQ: SPRY) was -1.12% drop from the session before settling in for the closing price of $13.44. A 52-week range for SPRY has been $7.55 – $18.51.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 59377.90% over the past five years. When this article was written, the company’s average yearly earnings per share was at -1764.58%. With a float of $56.10 million, this company’s outstanding shares have now reached $97.95 million.
Let’s look at the performance matrix of the company that is accounted for 160 employees. In terms of profitability, gross margin is 98.87%, operating margin of -3.46%, and the pretax margin is 9.29%.
ARS Pharmaceuticals Inc (SPRY) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward ARS Pharmaceuticals Inc stocks. The insider ownership of ARS Pharmaceuticals Inc is 42.88%, while institutional ownership is 51.05%. The most recent insider transaction that took place on Apr 07 ’25, was worth 615,075. In this transaction Director of this company sold 50,002 shares at a rate of $12.30, taking the stock ownership to the 210,346 shares. Before that another transaction happened on Apr 07 ’25, when Company’s Director proposed sale 50,002 for $12.30, making the entire transaction worth $615,051.
ARS Pharmaceuticals Inc (SPRY) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.45 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1764.58% per share during the next fiscal year.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Trading Performance Indicators
You can see what ARS Pharmaceuticals Inc (SPRY) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 14.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.64. Likewise, its price to free cash flow for the trailing twelve months is 100.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.08, a number that is poised to hit -0.34 in the next quarter and is forecasted to reach -0.55 in one year’s time.
Technical Analysis of ARS Pharmaceuticals Inc (SPRY)
ARS Pharmaceuticals Inc (NASDAQ: SPRY) saw its 5-day average volume 1.38 million, a negative change from its year-to-date volume of 1.56 million. As of the previous 9 days, the stock’s Stochastic %D was 18.78%. Additionally, its Average True Range was 0.80.
During the past 100 days, ARS Pharmaceuticals Inc’s (SPRY) raw stochastic average was set at 60.48%, which indicates a significant increase from 13.31% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.73% in the past 14 days, which was lower than the 64.15% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.02, while its 200-day Moving Average is $13.03. Nevertheless, the first resistance level for the watch stands at $13.64 in the near term. At $14.00, the stock is likely to face the second major resistance level. The third major resistance level sits at $14.34. If the price goes on to break the first support level at $12.95, it is likely to go to the next support level at $12.61. The third support level lies at $12.25 if the price breaches the second support level.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Key Stats
There are 98,211K outstanding shares of the company, which has a market capitalization of 1.31 billion. As of now, sales total 89,150 K while income totals 8,000 K. Its latest quarter income was 86,580 K while its last quarter net income were 49,930 K.
